Author:
Negri Armando L.,Brandemburg Vincent M.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74(6):2136–2143
2. Brandi L (2008) 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol—an active vitamin D analog: clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan Med Bull 55(4):186–210
3. Brown AJ, Finch J, Slatopolsky E (2002) Differential effects of 19-nor-1, 25-dihydroxyvitamin D(2) and 1, 25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 139(5):279–284
4. National Kidney Foundation (2003) K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S201
5. Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38(Suppl 5):S45–S50
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献